Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of ULTRASE MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
This study has been completed.
Study NCT00513682   Information provided by Axcan Pharma
First Received: August 7, 2007   Last Updated: April 9, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Pancreatic Insufficiency
Additional conditions recognized in this trial
Exocrine Pancreatic Insufficiency
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
ULTRASE MT20
Additional drug interventions recognized in this trial
Pancrelipase
More general drug interventions related to this trial
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Axcan Pharma


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services